246 related articles for article (PubMed ID: 20598756)
1. Targeting homologous recombination repair defects in cancer.
Evers B; Helleday T; Jonkers J
Trends Pharmacol Sci; 2010 Aug; 31(8):372-80. PubMed ID: 20598756
[TBL] [Abstract][Full Text] [Related]
2. Mutations in DNA mismatch repair genes: implications for DNA damage signaling and drug sensitivity (review).
Fedier A; Fink D
Int J Oncol; 2004 Apr; 24(4):1039-47. PubMed ID: 15010846
[TBL] [Abstract][Full Text] [Related]
3. Homologous recombination in cancer development, treatment and development of drug resistance.
Helleday T
Carcinogenesis; 2010 Jun; 31(6):955-60. PubMed ID: 20351092
[TBL] [Abstract][Full Text] [Related]
4. Selection for genome instability by DNA damage in human cells: unstable microsatellites and their consequences for tumourigenesis.
Hampson R
Radiat Oncol Investig; 1997; 5(3):111-4. PubMed ID: 9303066
[TBL] [Abstract][Full Text] [Related]
5. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation.
Moynahan ME; Cui TY; Jasin M
Cancer Res; 2001 Jun; 61(12):4842-50. PubMed ID: 11406561
[TBL] [Abstract][Full Text] [Related]
6. Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.
Zhu Y; Hu J; Hu Y; Liu W
Cancer Treat Rev; 2009 Nov; 35(7):590-6. PubMed ID: 19635647
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair.
Bolderson E; Richard DJ; Zhou BB; Khanna KK
Clin Cancer Res; 2009 Oct; 15(20):6314-20. PubMed ID: 19808869
[TBL] [Abstract][Full Text] [Related]
8. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.
Xu ZY; Loignon M; Han FY; Panasci L; Aloyz R
J Pharmacol Exp Ther; 2005 Aug; 314(2):495-505. PubMed ID: 15843498
[TBL] [Abstract][Full Text] [Related]
9. A novel host cell reactivation assay to assess homologous recombination capacity in human cancer cell lines.
Slebos RJ; Taylor JA
Biochem Biophys Res Commun; 2001 Feb; 281(1):212-9. PubMed ID: 11178982
[TBL] [Abstract][Full Text] [Related]
10. Analysis of DNA double-strand break repair pathways in mice.
Brugmans L; Kanaar R; Essers J
Mutat Res; 2007 Jan; 614(1-2):95-108. PubMed ID: 16797606
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
12. Apoptotic versus genotoxic potential of anti-tumor agents: a concept of duality in unity.
Bajic V; Milicevic Z; Potpervic-Spremo B; Nedeljkovic-Kurepa A
Med Hypotheses; 2003; 61(5-6):643-50. PubMed ID: 14592801
[TBL] [Abstract][Full Text] [Related]
13. Understanding DNA damage response and DNA repair pathways: applications to more targeted cancer therapeutics.
Kinsella TJ
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S42-51. PubMed ID: 19393835
[TBL] [Abstract][Full Text] [Related]
14. Targeting DNA damage and repair: embracing the pharmacological era for successful cancer therapy.
Aziz K; Nowsheen S; Pantelias G; Iliakis G; Gorgoulis VG; Georgakilas AG
Pharmacol Ther; 2012 Mar; 133(3):334-50. PubMed ID: 22197993
[TBL] [Abstract][Full Text] [Related]
15. Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil?
El-Awady RA; Saleh EM; Dahm-Daphi J
Anticancer Drugs; 2010 Mar; 21(3):277-87. PubMed ID: 20075715
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic deregulation of DNA repair and its potential for therapy.
Hegi ME; Sciuscio D; Murat A; Levivier M; Stupp R
Clin Cancer Res; 2009 Aug; 15(16):5026-31. PubMed ID: 19671858
[TBL] [Abstract][Full Text] [Related]
17. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes.
Kennedy RD; D'Andrea AD
J Clin Oncol; 2006 Aug; 24(23):3799-808. PubMed ID: 16896009
[TBL] [Abstract][Full Text] [Related]
18. Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance.
Henning W; Stürzbecher HW
Toxicology; 2003 Nov; 193(1-2):91-109. PubMed ID: 14599770
[TBL] [Abstract][Full Text] [Related]
19. Bacterial DNA repair genes and their eukaryotic homologues: 5. The role of recombination in DNA repair and genome stability.
Nowosielska A
Acta Biochim Pol; 2007; 54(3):483-94. PubMed ID: 17893749
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of drug resistance.
Longley DB; Johnston PG
J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
